2.9012

4.89% 0.1412

Solid Biosciences Inc (SLDB)

Overview News Price History Option Chain Financials Why SLDB Down? Discussions Forecast Stock Split

Solid Biosciences Inc stock is traded at $2.9012, with a volume of 1.09M. It is up +4.89% in the last 24 hours and up +7.22% over the past month. Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.

Previous Close:

$2.76

Open:

$2.89

24h Volume:

1.09M

Relative Volume:

0.41

Market Cap:

$327.83M

Revenue:

$14.79M

Net Income/Loss:

$-102.44M

P/E Ratio:

-0.9543

EPS:

-3.04

Net Cash Flow:

$-91.73M

1W Performance:

-31.56%

1M Performance:

+7.22%

6M Performance:

-47.46%

1Y Performance:

-72.14%

1-Day Range:

$2.76

$3.005

1-Week Range:

$2.52

$4.189

52-Week Range:

$2.45

$10.68

Solid Biosciences Inc Stock (SLDB) Company Profile

Name

Solid Biosciences Inc

Sector

Healthcare (1153)

Industry

Biotechnology (676)

Phone

617-337-4680

Address

500 RUTHERFORD AVENUE, CHARLESTOWN, MA

Employee

100

Twitter

@SolidBioDMD

Next Earnings Date

2024-11-06

Latest SEC Filings

SLDB's Discussions on Twitter

Compare SLDB with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
SLDB Solid Biosciences Inc	2.905	327.83M	14.79M	-102.44M	-91.73M	-3.04
VRTX Vertex Pharmaceuticals Inc	439.61	128.45B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	577.92	65.17B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	559.58	40.09B	2.58B	1.06B	-1.28B	16.33
ALNY Alnylam Pharmaceuticals Inc	266.49	35.67B	2.35B	-269.70M	-75.39M	-2.09
ONC Beigene Ltd Adr	231.39	27.44B	3.81B	-644.79M	-669.77M	-6.24

Solid Biosciences Inc Stock (SLDB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-08-25	Initiated	Truist	Buy
Dec-13-24	Initiated	Wedbush	Outperform
Dec-10-24	Initiated	JMP Securities	Mkt Outperform
Jul-15-24	Upgrade	JP Morgan	Neutral → Overweight
Jun-24-24	Upgrade	Leerink Partners	Market Perform → Outperform
May-31-24	Resumed	Piper Sandler	Overweight
Mar-28-24	Initiated	William Blair	Outperform
Mar-15-24	Initiated	Citigroup	Buy
Mar-14-24	Upgrade	Piper Sandler	Neutral → Overweight
Dec-08-23	Initiated	H.C. Wainwright	Buy
Jul-12-21	Initiated	Piper Sandler	Neutral
May-27-21	Initiated	Jefferies	Buy
Mar-16-21	Upgrade	SVB Leerink	Mkt Perform → Outperform
Mar-09-21	Initiated	Barclays	Overweight
Jan-08-21	Upgrade	Credit Suisse	Underperform → Neutral
Jul-28-20	Downgrade	SVB Leerink	Outperform → Mkt Perform
May-07-20	Downgrade	Evercore ISI	Outperform → In-line
Oct-11-19	Initiated	Evercore ISI	Outperform
Aug-29-19	Downgrade	Citigroup	Neutral → Sell
Aug-19-19	Upgrade	SVB Leerink	Mkt Perform → Outperform
Aug-16-19	Upgrade	Chardan Capital Markets	Neutral → Buy
May-14-19	Downgrade	Credit Suisse	Neutral → Underperform
May-14-19	Downgrade	Goldman	Neutral → Sell
Feb-08-19	Upgrade	Citigroup	Sell → Neutral
Feb-08-19	Downgrade	SVB Leerink	Outperform → Mkt Perform
Nov-06-18	Initiated	Citigroup	Sell
Sep-06-18	Initiated	Credit Suisse	Neutral

View All

Solid Biosciences Inc Stock (SLDB) Latest News

May 01, 2025

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

May 01, 2025

Solid Biosciences Expands Team: 81,000 RSUs Awarded to 7 Strategic New Hires - Stock Titan

May 01, 2025

Apr 30, 2025

Solid Biosciences to Participate at The Citizens Life Sciences Conference - The Manila Times

Apr 30, 2025

Exclusive: Solid Biosciences CEO Ready to Reveal Latest Company Vision at Major Life Sciences Event - Stock Titan

Apr 30, 2025

Apr 29, 2025

Solid Biosciences to Present at the American Society of Gene and Cell Therapy's 28th Annual Meeting - The Manila Times

Apr 29, 2025

Solid Biosciences to Present Phase 1/2 Trial Data for SGT-003 Gene Therapy at ASGCT 2025 Annual Meeting - Nasdaq

Apr 29, 2025

Solid Biosciences to Present at the American Society of Gene and Cell Therapy’s 28th Annual Meeting - GlobeNewswire

Apr 29, 2025

New Duchenne Treatment Breakthrough: Solid Bio Unveils Critical Gene Therapy Trial Results at Major Conference - Stock Titan

Apr 29, 2025

Apr 28, 2025

Montai Therapeutics Appoints Allison Bogosian, JD, as Chief People and Administrative Officer - Business Wire

Apr 28, 2025

Apr 21, 2025

Piper Sandler Remains a Buy on Solid Biosciences (SLDB) - The Globe and Mail

Apr 21, 2025

Apr 19, 2025

Certain Restricted Stock Units of Solid Biosciences Inc. are subject to a Lock-Up Agreement Ending on 20-APR-2025. - marketscreener.com

Apr 19, 2025

Certain Common Stock of Solid Biosciences Inc. are subject to a Lock-Up Agreement Ending on 20-APR-2025. - marketscreener.com

Apr 19, 2025

Apr 16, 2025

Solid Biosciences stock hits 52-week low at $2.47 By Investing.com - Investing.com South Africa

Apr 16, 2025

Solid Biosciences stock hits 52-week low at $2.47 - Investing.com Australia

Apr 16, 2025

Apr 13, 2025

Can Solid Biosciences Challenge Sarepta in the DMD Market? - MSN

Apr 13, 2025

Apr 08, 2025

Solid Biosciences: A Strong Buy As An Emerging Biotech In The Gene Therapy Space - Seeking Alpha

Apr 08, 2025

Apr 07, 2025

Solid Biosciences stock hits 52-week low at $2.88 - Investing.com Australia

Apr 07, 2025

Solid Biosciences stock hits 52-week low at $2.88 By Investing.com - Investing.com South Africa

Apr 07, 2025

Solid Biosciences to Participate at Upcoming Investor Conferences - GlobeNewswire

Apr 07, 2025

Exclusive Access: Solid Biosciences Leadership Team Headlines Two Major Healthcare Conferences - Stock Titan

Apr 07, 2025

Apr 01, 2025

Solid Biosciences reports inducement grants under Nasdaq listing rule - TipRanks

Apr 01, 2025

Solid Biosciences Expands Team with 43,374 RSU Grants in Strategic Hiring Move - Stock Titan

Apr 01, 2025

Mar 20, 2025

Sarepta safety update on Elevidys boosts Regenxbio, hurts Solid Bio - MSN

Mar 20, 2025

Truist Financial Keeps Their Buy Rating on Solid Biosciences (SLDB) - The Globe and Mail

Mar 20, 2025

Mar 19, 2025

Solid Biosciences Inc.'s (NASDAQ:SLDB) market cap dropped US$53m last week; Private equity firms bore the brunt - simplywall.st

Mar 19, 2025

Mar 18, 2025

Regenxbio stock up, Solid Bio down post Sarepta update (RGNX) - Seeking Alpha

Mar 18, 2025

Mar 14, 2025